Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.
Q3 2025 Management View CEO Alexander Karp described the quarter as delivering "arguably the best results that any software ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback